Aberdeen Group plc Sells 234,399 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Aberdeen Group plc lowered its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 22.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 796,802 shares of the company’s stock after selling 234,399 shares during the period. Aberdeen Group plc owned approximately 1.16% of Eyepoint Pharmaceuticals worth $11,346,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at $1,200,000. Walleye Capital LLC lifted its stake in Eyepoint Pharmaceuticals by 500.6% during the 2nd quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock valued at $1,877,000 after acquiring an additional 166,243 shares during the period. XTX Topco Ltd grew its stake in shares of Eyepoint Pharmaceuticals by 215.4% in the second quarter. XTX Topco Ltd now owns 137,950 shares of the company’s stock worth $1,298,000 after acquiring an additional 94,210 shares during the period. R Squared Ltd bought a new position in Eyepoint Pharmaceuticals during the second quarter valued at approximately $100,000. Finally, Stempoint Capital LP purchased a new stake in Eyepoint Pharmaceuticals in the second quarter worth approximately $3,098,000. 99.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada upped their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of “Buy” and an average target price of $29.25.

Eyepoint Pharmaceuticals Stock Up 2.4%

NASDAQ:EYPT opened at $14.70 on Friday. The business’s 50-day simple moving average is $15.73 and its two-hundred day simple moving average is $13.85. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $19.11. The stock has a market cap of $1.22 billion, a PE ratio of -4.92 and a beta of 1.76.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.46% of the stock is owned by corporate insiders.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.